Clifford Rostomily
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Clifford Rostomily has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Alan Aderem
Center for Global Infectious Disease Research, Seattle Children’s Research Institute, Seattle, WA 98109
2 shared publications Alex Xu
Institute for Systems Biology, Seattle, WA 98109, USA
2 shared publications- Alissa C. Rothchild
Department of Veterinary and Animal Sciences, University of Massachusetts Amherst, Amherst, MA 01003, USA
2 shared publications - Andrew T. Magis
Institute for Systems Biology, Seattle, WA 98109, USA
2 shared publications Brett Smith
Institute for Systems Biology, Seattle, WA 98109, USA
2 shared publications- Christopher Lausted
Institute for Systems Biology, Seattle, USA
2 shared publications
Latest Publications
- 8 December 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 13 (661)
A small sustained increase in NOD1 abundance promotes ligand-independent inflammatory and oncogene transcriptional responses
A disproportionately large response is induced by small increases in the abundance of a pathogen sensor.
- 8 December 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 13 (661)
A small sustained increase in NOD1 abundance promotes ligand-independent inflammatory and oncogene transcriptional responses
A disproportionately large response is induced by small increases in the abundance of a pathogen sensor.
- Top Cited PapersOpen Access
Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19
Top Cited PapersOpen AccessMulti-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19
- Open Access
- 1 January 2020
- Published by Elsevier in SSRN Electronic Journal
Multiomic Immunophenotyping of COVID-19 Patients Reveals Early Infection Trajectories
Host immune responses play central roles in controlling SARS-CoV2 infection, yet remain incompletely characterized and understood. Here, we present a comprehensive immune response map spanning 454 proteins and 847 metabolites in plasma integrated with single-cell multi-omic assays of 221,748 PBMCs in which whole transcriptome, 192 surface proteins, and T and B cell receptor sequence were analyzed within the context of clinical measures from 50 COVID19 patient samples. Our study reveals novel cellular subpopulations, such as proliferative exhausted CD8+ and CD4+ T cells, and cytotoxic CD4+ T cells, that may be features of severe COVID-19 infection. We condensed over 1 million immune features into a single immune response axis that independently aligns with many clinical features and is also strongly associated with disease severity. Our study represents an important resource towards understanding the heterogeneous immune responses of COVID-19 patients and may provide key information for informing therapeutic development.
- 1 January 2020
- Published by Elsevier in SSRN Electronic Journal
Open AccessMultiomic Immunophenotyping of COVID-19 Patients Reveals Early Infection Trajectories
Host immune responses play central roles in controlling SARS-CoV2 infection, yet remain incompletely characterized and understood. Here, we present a comprehensive immune response map spanning 454 proteins and 847 metabolites in plasma integrated with single-cell multi-omic assays of 221,748 PBMCs in which whole transcriptome, 192 surface proteins, and T and B cell receptor sequence were analyzed within the context of clinical measures from 50 COVID19 patient samples. Our study reveals novel cellular subpopulations, such as proliferative exhausted CD8+ and CD4+ T cells, and cytotoxic CD4+ T cells, that may be features of severe COVID-19 infection. We condensed over 1 million immune features into a single immune response axis that independently aligns with many clinical features and is also strongly associated with disease severity. Our study represents an important resource towards understanding the heterogeneous immune responses of COVID-19 patients and may provide key information for informing therapeutic development.